GBD 2019: Global Prevalence and Burden of Depressive and Anxiety Disorders in 204 Countries and Territories in 2020 Due to the COVID-19 Pandemic
2021
This article from The Lancet estimates the global prevalence and burden of depressive and anxiety disorders using data from the Global Burden of Disease (GBD) Study 2019. This paper seeks to provide policymakers and health officials an understanding of the health challenges the globe or their individual countries face, as well as how these challenges change over time. The GBD papers incorporate the prevalence of a disease, injury, or risk factor and the relative harm they cause to align health systems with the populations they serve.
Led by the Institute for Health Metrics and Evaluation (IHME) at the University of Washington, GBD is a global effort with researchers from over 150 countries and territories. IHME and other partnering organizations have developed numerous resources to disseminate and visualize the findings of the GBD studies, data visualizations and interactives, country profiles, policy reports, research articles, infographics, and the GBD Results Tool, which allows users to search GBD data.
Source:
COVID-19 Mental Disorders Collaborators. Global Prevalence and Burden of Depressive and Anxiety Disorders in 204 Countries and Territories in 2020 Due to the COVID-19 Pandemic. The Lancet 2021; 398(10312): 1700-1712.
DOI: https://doi.org/10.1016/S0140-6736(21)02143-7.